These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34048893)

  • 41. Cytopathic Effect (CPE )-Based Drug Screening Assay for SARS-CoV-2.
    Ng YL; Mok CK; Chu JJH
    Methods Mol Biol; 2022; 2452():379-391. PubMed ID: 35554918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2.
    Wang SF; Chen KH; Wang SY; Yarmishyn AA; Lai WY; Lin YY; Wang ML; Chou SJ; Yang YP; Chang YL
    J Chin Med Assoc; 2020 Aug; 83(8):712-718. PubMed ID: 32433345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives.
    Yan K; Rawle DJ; Le TT; Suhrbier A
    Virol J; 2021 Jun; 18(1):123. PubMed ID: 34107996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay.
    Zhang J; Yan H; Yan G; Liu X; Wang Y; Chen Y
    STAR Protoc; 2022 Dec; 3(4):101794. PubMed ID: 36317181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current therapies under investigation for COVID-19: potential COVID-19 treatments.
    Weisberg E; Sattler M; Yang PL; Parent A; Gray N; Griffin JD
    Can J Physiol Pharmacol; 2020 Aug; 98(8):483-489. PubMed ID: 32640179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase.
    Zeng J; Weissmann F; Bertolin AP; Posse V; Canal B; Ulferts R; Wu M; Harvey R; Hussain S; Milligan JC; Roustan C; Borg A; McCoy L; Drury LS; Kjaer S; McCauley J; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2405-2423. PubMed ID: 34198322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic approaches for SARS-CoV-2 infection.
    Gupta A; Pradhan A; Maurya VK; Kumar S; Theengh A; Puri B; Saxena SK
    Methods; 2021 Nov; 195():29-43. PubMed ID: 33962011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluorogenic
    Ihssen J; Faccio G; Yao C; Sirec T; Spitz U
    STAR Protoc; 2021 Sep; 2(3):100793. PubMed ID: 34423318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.
    Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK
    Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biochemical screening for SARS-CoV-2 main protease inhibitors.
    Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
    PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
    Shagufta ; Ahmad I
    Eur J Med Chem; 2021 Mar; 213():113157. PubMed ID: 33486200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.
    Doijen J; Heo I; Temmerman K; Vermeulen P; Diels A; Jaensch S; Burcin M; Van den Broeck N; Raeymaekers V; Peremans J; Konings K; Clement M; Peeters D; Van Loock M; Koul A; Buyck C; Van Gool M; Van Damme E
    Antiviral Res; 2024 Feb; 222():105789. PubMed ID: 38158129
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
    Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks BM; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W
    Front Pharmacol; 2020; 11():592737. PubMed ID: 33708112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Establishment, optimization and validation of a fluorescence polarization-based high-throughput screening assay targeting cathepsin L inhibitors.
    Zhou W; You B; Zhao X; Si S; Li Y; Zhang J
    SLAS Discov; 2024 Apr; 29(3):100153. PubMed ID: 38518956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High content screening strategies for large-scale compound libraries with a focus on high-containment viruses.
    Subramani C; Sharma G; Chaira T; Barman TK
    Antiviral Res; 2024 Jan; 221():105764. PubMed ID: 38008193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the Coronavirus Disease 2019 Pandemic.
    Fader KA; Zhang J; Menetski JP; Thadhani RI; Antman EM; Friedman GS; Ramaiah SK; Vaidya VS
    J Pharmacol Exp Ther; 2021 Jan; 376(1):12-20. PubMed ID: 33115823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.